459 related articles for article (PubMed ID: 27569869)
1. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
[TBL] [Abstract][Full Text] [Related]
3. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
[TBL] [Abstract][Full Text] [Related]
6. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
8. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
[TBL] [Abstract][Full Text] [Related]
9. Identification of new SNPs associated with severe toxicity to capecitabine.
Pellicer M; García-González X; García MI; Robles L; Grávalos C; García-Alfonso P; Pachón V; Longo F; Martínez V; Blanco C; Iglesias I; Sanjurjo M; López-Fernández LA
Pharmacol Res; 2017 Jun; 120():133-137. PubMed ID: 28347776
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
[TBL] [Abstract][Full Text] [Related]
11. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
[TBL] [Abstract][Full Text] [Related]
12. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
13. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
14. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
15. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
Lam SW; van der Noort V; van der Straaten T; Honkoop AH; Peters GJ; Guchelaar HJ; Boven E
Pharmacol Res; 2018 Feb; 128():122-129. PubMed ID: 28827188
[TBL] [Abstract][Full Text] [Related]
16. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
17. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
[TBL] [Abstract][Full Text] [Related]
18. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
19. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
O'Donnell PH; Trubetskoy V; Nurhussein-Patterson A; Hall JP; Nath A; Huo D; Fleming GF; Ingle JN; Abramson VG; Morrow PK; Storniolo AM; Forero A; Van Poznak C; Liu MC; Chang JC; Merkel DE; Peppercorn JM; Rugo HS; Dees EC; Hahn OM; Hoffman PC; Rosner GL; Huang RS; Ratain MJ; Cox N; Olopade OI; Wolff AC; Dolan ME; Nanda R;
Breast Cancer Res Treat; 2020 Jun; 181(3):623-633. PubMed ID: 32378051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
